17543CON2(BAR) (AP) PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrews et al.

Serial No.: Not yet assigned

Filed: Herewith

For: Kinase Inhibitors for the Treatment of Disease

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail (EV193718046US) in an envelope addressed to: Mail Sto Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandrai, VA 22313-1450 on:

Date of Deposit: 4/20/2004
Person making Deposit: BONNIE FERGUSON
Signature: Bonnie Ferguson
Date of Signature: 4/20/2004

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentablility of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough. Copies of the references are not provided with this application as they were submitted to the USPTO with Serial No. 10/389,416, filed March 13, 2003.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

Date: 4/20/04

Respectfully submitted,

R J Baran

Robert J. Baran
Reg. No. 25,806
ALLERGAN, INC. -T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4669
Fax: 714-246-4249

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE FORM PTO-1449

Sheet 1 of 2

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17543CON2(AP)	**SERIAL NO.:** Not assigned
APPLICANT: Andrews et al	**TITLE:** KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
FILING DATE: Submitted herewith	**GROUP:** Not Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	4,966,849	10/30/1990	Vallee et al			
	AB	5,330,992	7/19/1994	Eissenstat et al			
	AC	5,217,999	6/8/1993	Levitzki et al			
	AD	5,302,606	4/12/1994	Spada et al			
	AE	5,792,783	8/11/1998	Tang et al			
	AF	5,834,504	11/10/1998	Tang et al			
	AG	5,883,113	3/16/1999	Tang et al			
	AH	5,883,116	3/16/1999	Tang et al			
	AI	5,886,020	3/23/1999	Tang et al			
	AJ	6,316,635	11/13/2001	Tang et al			
	AK	2002/0037878A1	3/28/2002	Moon et al			
	AL	2002/0035140A1	3/21/2002	Moon et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AM	WO 94/10202	5/11/1994	PCT			
	AN	WO 94/03427	2/17/1994	PCT			
	AO	WO 92/21660	12/10/1992	PCT			
	AP	WO 91/15495	10/17/1991	PCT			
	AQ	WO 94/14808	7/7/1994	PCT			
	AR	WO 92/20642	11/26/1992	PCT			
	AS	WO 01/90103	11/29/2001	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AT		Plowman et al, "Receptor Tyrosine Kinases as Targets for Drug Intervention",1994, DN&P 7(6): 334-339
	AU		Bolen, "Nonreceptor tyrosine protein kinases", 1993, Oncogen 8: 2025-2031
	AV		Kendall et al, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor", 1994, Proc. Natl'l Acad. Sci 90: 10705-10709
	AW		Kim et al, "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo", Nature 362, 841-844
	AX		Jellinek et al, "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor", Biochemistry 33: 10450-10456
	AY		Takano et al, "Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase C.", 1993, Mol. Bio. Cell 4: 2072, Page 358A
	AZ		Kinsella et al, "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel", 1992, Experimental Cell Research, 199: 56-62
	BA		Wright et al, "Inibition of Angiogenesis In Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032", 1992, Journal of Cellular Phys. 152: 448-457
	BB		Mariani et al, "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor",1994, Proc. Am. Assoc. Cancer Res. 35:2268; Page 381
	BC		Castro et al , "Quantitative Image Analysis of Laser-induced Choroidal Neovascularization in Rat", Exp. Eye Res. 2000; 71:523-55
	BD		Bundgaard et al, "Hydrolysis of N-(α-hydroxyalkyl)amide derivatives: implications for the design of N-acyloxyalkyl-type prodrugs", Int. J. of Pharmaceutics 22 (1984); 45-56
	BE		Bundgaard et al, ?Prodrugs as drug delivery systems, 43. O-Acyloxymethyl salicylamide N-Mannich bases as double prodrug forms for amines", Int. J. of Pharmaceutics 29 (1986); 19-28
	BF		Bundgaard et al, "A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group", J. Med. Chem. 32 (1989) 2503-2507
	BG		Bundgaard et al,"Prodrugs as drug delivery systems. XIX. Bioreversible derivatization of aromatic amines by formation of N-Mannich bases with succinimide", Chem. Abstracts 95, 138493f
	BH		Bundgaard et al, "Hydrolysis of N-Mannich bases and its consequences for the biological testing of such agents", Chem. Abstracts 95, 138592n

EXAMINER_____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17543CON2(AP)	**SERIAL NO.:** Not assigned
APPLICANT: Andrews et al	**TITLE:** KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
FILING DATE: Submitted herewith	**GROUP:** Not Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	BI		Alminger et al, "(Pyridinylmethyl)sulfinylbenzimidazole derivatives as antiulcer agents, their preparation and formulations containing them", Chem. Abstracts 110, 57664p
	BJ		Buur et al, "Prodrugs of cimetidine with increased lipophilicity; N-acyloxymethyl and N-alkoxycarbonyl derivatives", Chem. Abstracts 115, 64029s
	BK		Hansen et al, "Carbamate ester prodrugs of dopaminergic compounds: synthesis, stability, and bioconversion", Chem Abstracts 115, 189582y
	BL		Bundgaard et al, "Phenyl carbamates of amino acids as prodrugs forms for protecting phenols against first-pass metabolism", Chem. Abstracts 117, 14347q
	BM		Jensen et al, N-Substituted (aminomethyl)benzoate 21-esters of corticosteroids as water-soluble, solution-stable and biolabile prodrugs", Chem. Abstracts 117, 55790x
	BN		Thomsen et al, "Evaluation of phenyl carbamates of ethyl diamines as cyclization-activated prodrug forms for protecting phenols against first-pass metabolism", Chem Abstracts 123, 17593b

EXAMINER_____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.